Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Smoking triggers epigenetic damage linked to macular degeneration

26

Feb 2026

Smoking triggers epigenetic damage linked to macular degeneration

Through a series of experiments supported by the National Institutes of Health, Johns Hopkins Medicine (JHM) researchers say they have advanced understanding of how smoking damages the eye and contributes to the development of age-related macular degeneration (AMD), the leading worldwide cause of visual impairment and blindness among people 50 and older.

Researchers reveal why SuperAgers retain youthful brain cell signatures into their 80s

26

Feb 2026

Researchers reveal why SuperAgers retain youthful brain cell signatures into their 80s

Researchers used single-nucleus RNA sequencing and chromatin accessibility profiling to map human hippocampal neurogenesis across adulthood, aging, and Alzheimer’s disease. They found that chromatin accessibility changes, more than gene expression alone, distinguish healthy aging, preclinical pathology, Alzheimer’s disease, and cognitive resilience in SuperAgers.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.